Clinical Trials Logo

Clinical Trial Summary

This study aimed to analyze the safety of 90-min intravenous rapid infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma and to provide evidence for the applicability of rapid infusion regimens in chemotherapy in China.


Clinical Trial Description

n/a


Study Design


NCT number NCT05510219
Study type Interventional
Source The First Affiliated Hospital with Nanjing Medical University
Contact shuangshuang xing, master
Phone +8613851784715
Email sryxss@163.com
Status Recruiting
Phase Phase 2
Start date January 1, 2022
Completion date December 31, 2023